Literature DB >> 1774048

The diagnosis and treatment of donovanosis (granuloma inguinale).

J Richens1.   

Abstract

Donovanosis is a predominantly tropical cause of genital ulcer occurring chiefly in small endemic foci in all continents except Europe. Diagnosis requires the careful collection, staining and examination of smears or biopsies of characteristic genital and, occasionally, extragenital lesions for demonstration of the pathognomonic Donovan bodies (Calymmatobacterium granulomatis) within histiocytes. Successful isolation of C. granulomatis has rarely proved feasible, the last report being in 1962. Donovanosis has a characteristic histopathological picture which occasionally simulates epithelioma. The antibiotics reported as showing good activity in donovanosis are those with good activity against gram negative bacilli and whose lipid solubility ensures good intracellular penetration. They include streptomycin, chloramphenicol, erythromycin, lincomycin, cotrimoxazole and the tetracyclines. More recently, good results have been reported with norfloxacin and thiamphenicol. The treatment of donovanosis in pregnant women and patients with AIDS poses special problems. Complications of donovanosis such as elephantiasis, stricture and pelvic abscess may require surgery. Contacts should be traced for examination but only treated if lesions are found.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1774048      PMCID: PMC1194766          DOI: 10.1136/sti.67.6.441

Source DB:  PubMed          Journal:  Genitourin Med        ISSN: 0266-4348


  109 in total

1.  Studies on granuloma inguinale. V. Isolation of a bacterium resembling Donovania granulomatis from the faeces of a patient with granuloma inguinale.

Authors:  J GOLDBERG
Journal:  Br J Vener Dis       Date:  1962-06

2.  The use of tetracycline phosphate complex in a venereal disease clinic.

Authors:  M MARMELL; A PRIGOT
Journal:  Antibiotic Med Clin Ther (New York)       Date:  1959-02

3.  Treatment of granuloma inguinale with triacetyloleandomycin. Report of a case.

Authors:  F KERDEL-VEGAS; J CONVIT; J M SOTO
Journal:  Arch Dermatol       Date:  1961-08

4.  Donovanosis of the anus in the male; an epidemiological consideration.

Authors:  M MARMELL
Journal:  Br J Vener Dis       Date:  1958-12

5.  Disseminated granuloma inguinale and its relationship to granuloma of the cervix and pregnancy.

Authors:  W B CHERNY; C P JONES; C H PEETE
Journal:  Am J Obstet Gynecol       Date:  1957-09       Impact factor: 8.661

6.  Granuloma inguinale of the epididymis.

Authors:  J R JANNACH
Journal:  Br J Vener Dis       Date:  1958-03

7.  Oleandomycin in the treatment of donovanosis.

Authors:  M MARMELL; A PRIGOT
Journal:  Antibiotic Med Clin Ther (New York)       Date:  1956-09

8.  Granuloma inguinale of the cervix.

Authors:  J Q ADAMS; H PACKER
Journal:  South Med J       Date:  1955-01       Impact factor: 0.954

9.  The effect of tetracycline hydrochloride in lymphogranuloma venereum and donovanosis.

Authors:  A de L MAYNARD; A PRIGOT; M MARMELL
Journal:  Am J Syph Gonorrhea Vener Dis       Date:  1954-11

10.  Tetracycline (tetracyn) in the treatment of donovanosis.

Authors:  M MARMELL; A PRIGOT
Journal:  Harlem Hosp Bull       Date:  1955-06
View more
  5 in total

1.  Donovanosis (granuloma inguinale).

Authors:  J Richens
Journal:  Sex Transm Infect       Date:  2006-12       Impact factor: 3.519

2.  Pilot study of azithromycin in the treatment of genital donovanosis.

Authors:  F J Bowden; J Mein; C Plunkett; I Bastian
Journal:  Genitourin Med       Date:  1996-02

3.  Failure of trimethoprim in the treatment of donovanosis.

Authors:  K Birthistle; J Greig; P Hay
Journal:  Genitourin Med       Date:  1997-06

Review 4.  Global eradication of donovanosis: an opportunity for limiting the spread of HIV-1 infection.

Authors:  N O'Farrell
Journal:  Genitourin Med       Date:  1995-02

5.  Ceftriaxone in the treatment of chronic donovanosis in central Australia.

Authors:  A Merianos; M Gilles; J Chuah
Journal:  Genitourin Med       Date:  1994-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.